Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1953554 | 0.88 | MET (0.83) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL3101484 | 0.80 | MET (1.00) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL15113585 | 0.78 | MET (0.68) | METNQO2 | |
| SCHEMBL3094677 | 0.77 | MET (0.67) | METNQO2 | |
| SCHEMBL3092398 | 0.77 | MET (0.67) | METNQO2 | |
| SCHEMBL3087944 | 0.76 | MET (0.66) | METNQO2 | |
| SCHEMBL3092070 | 0.76 | MET (0.66) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL3083844 | 0.76 | MET (0.64) | MET | |
| SCHEMBL3087965 | 0.75 | MET (0.64) | METCHEK1NEK2LIMK1TYRO3 | |
| SCHEMBL3095747 | 0.75 | MET (0.63) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136819-A1 | 6-THIOXOPYRIDAZINE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2011-06-09 | — | — | US | claimed |
| US-20110136819-A1 | 6-THIOXOPYRIDAZINE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2011-06-09 | — | — | US | disclosed |
| US-20110136819-A1 | 6-THIOXOPYRIDAZINE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2011-06-09 | — | — | US | disclosed |
| US-20110136819-A1 | 6-THIOXOPYRIDAZINE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2011-06-09 | — | — | US | disclosed |
| EP-2176236-A1 | 6-THIOXO-PYRIDAZINE DERIVATIVES | Merck Patent GmbH (DE) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009024221-A1 | 6-THIOXO-PYRIDAZINE DERIVATIVES | MERCK PATENT GBMH (DE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024221-A1 | 6-THIOXO-PYRIDAZINE DERIVATIVES | MERCK PATENT GBMH (DE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136819-A1 | 6-THIOXOPYRIDAZINE DERIVATIVES | RET, ABL1, JAK2 | MET 4/4885MEN1 583/4885KMT2A 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.